{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:27:37Z","timestamp":1793813257266,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CRP-17-111-01-CDD"],"award-info":[{"award-number":["CRP-17-111-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101044047"],"award-info":[{"award-number":["101044047"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137008"],"award-info":[{"award-number":["JP256f0137008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-23-IAHU-0002"],"award-info":[{"award-number":["ANR-23-IAHU-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA220497"],"award-info":[{"award-number":["R35CA220497"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.annonc.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:36Z","timestamp":1787067816000},"page":"1549-1563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"F.","family":"Facchinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9572-4524","authenticated-orcid":false,"given":"L.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4306-7979","authenticated-orcid":false,"given":"M.","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-9396","authenticated-orcid":false,"given":"S.","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"M.","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-1095","authenticated-orcid":false,"given":"M.","family":"Makarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-0883","authenticated-orcid":false,"given":"I.","family":"Alonso Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4808-0308","authenticated-orcid":false,"given":"R.","family":"Minari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tuladhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-2825","authenticated-orcid":false,"given":"K.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4762-1793","authenticated-orcid":false,"given":"A.","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Odintsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-2142","authenticated-orcid":false,"given":"M.K.A.","family":"Koivu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-6703","authenticated-orcid":false,"given":"A.","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-2960","authenticated-orcid":false,"given":"J.K.","family":"Rotow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-827X","authenticated-orcid":false,"given":"J.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"LoPiccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"M.","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-1093","authenticated-orcid":false,"given":"A.T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"P.A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.08.004_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.08.004_bib2","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1200\/JCO.2023.41.16_suppl.9108","article-title":"Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: a multi-institutional cohort","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.08.004_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.08.004_bib4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2026.08.004_bib5","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jtho.2024.09.184","article-title":"MA12.03 FLAURA2: resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib \u00b1 platinum-pemetrexed","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2026.08.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107917","article-title":"Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-na\u00efve advanced non-small cell lung cancer","volume":"195","author":"Tamiya","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2026.08.004_bib7","article-title":"Genomic profiling of epidermal growth factor receptor mutation-positive non-small cell lung cancer post-progression on first-line osimertinib: phase II ORCHARD study","author":"Yu","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.08.004_bib8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2026.08.004_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.08.004_bib10","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.08.004_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.08.004_bib12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.annonc.2022.01.004","article-title":"Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients","volume":"33","author":"Chen","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.08.004_bib13","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","article-title":"Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2026.08.004_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103935","article-title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"9","author":"Li","year":"2024","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.annonc.2026.08.004_bib15","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.jtho.2019.12.132","article-title":"Erdafitinib overcomes FGFR3-TACC3-mediated resistance to osimertinib","volume":"15","author":"Haura","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.08.004_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12943-024-02134-4","article-title":"Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development","volume":"23","author":"Vasseur","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.08.004_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.08.004_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.08.004_bib19","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-23-3302","article-title":"Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC","volume":"30","author":"Pang","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.annonc.2026.08.004_bib20","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.annonc.2026.08.004_bib21","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.08.004_bib22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"issue":"31","key":"10.1016\/j.annonc.2026.08.004_bib23","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.annonc.2026.08.004_bib24","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.08.004_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06907","article-title":"Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma","volume":"4","author":"Unni","year":"2015","journal-title":"Elife"},{"issue":"19","key":"10.1016\/j.annonc.2026.08.004_bib26","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2026.08.004_bib27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm.3930","article-title":"RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer","volume":"21","author":"Hrustanovic","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.08.004_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1078-0432.CCR-19-1667","article-title":"Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer","volume":"26","author":"Rotow","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2026.08.004_bib29","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.18632\/oncotarget.3311","article-title":"Activation of RAS family members confers resistance to ROS1 targeting drugs","volume":"6","author":"Cargnelutti","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.annonc.2026.08.004_bib30","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov"},{"issue":"6758","key":"10.1016\/j.annonc.2026.08.004_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.annonc.2026.08.004_bib32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-25-0679","article-title":"A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer","volume":"16","author":"Centonze","year":"2026","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.annonc.2026.08.004_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.08.004_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2026.08.004_bib35","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2026.08.004_bib36","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.annonc.2026.08.004_bib37","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.08.004_bib38","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2026.08.004_bib39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.annonc.2026.08.004_bib40","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.annonc.2026.08.004_bib41","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2026.08.004_bib42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","article-title":"Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the Lung Cancer Mutation Consortium Experience","volume":"14","author":"El Osta","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.08.004_bib43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","article-title":"Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer","volume":"33","author":"Ricciuti","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.08.004_bib44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"issue":"29","key":"10.1016\/j.annonc.2026.08.004_bib45","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8013","key":"10.1016\/j.annonc.2026.08.004_bib46","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.annonc.2026.08.004_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.08.004_bib48","doi-asserted-by":"crossref","unstructured":"Riess J, Haura E, Yaeger R, et al. Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Presented at: 2026 AACR Annual Meeting; April 17-22, 2026; San Diego, CA. Abstract CT021.","DOI":"10.1158\/1538-7445.AM2026-CT021"},{"issue":"3","key":"10.1016\/j.annonc.2026.08.004_bib49","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"6MO: safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2026.08.004_bib50","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.08.004_bib51","article-title":"Efficacy and tolerability of osimertinib and sotorasib combination treatment for osimertinib resistance caused by KRAS G12C mutation: a report of two cases","volume":"7","author":"Ernst","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2026.08.004_bib52","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.08.004_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103894","article-title":"Long-term impact of first-line amivantamab plus lazertinib versus osimertinib on mechanisms of acquired resistance in MARIPOSA: a brief report","author":"Hayashi","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.08.004_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.annonc.2026.08.004_bib55","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.08.004_bib56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2026.01.004","article-title":"Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib","volume":"37","author":"Ellis","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.08.004_bib57","article-title":"Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma","volume":"7","author":"Hadoux","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426014584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426014584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:31:25Z","timestamp":1793809885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426014584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0923753426014584"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.08.004","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}